<DOC>
	<DOCNO>NCT00351065</DOCNO>
	<brief_summary>This study design evaluate efficacy safety SK3530 tablet find optimal dose dosage schedule oral administration patient erectile dysfunction .</brief_summary>
	<brief_title>Phase II Trial SK3530 Erectile Dysfunction</brief_title>
	<detailed_description>Double-blind , Placebo-controlled , randomize , parallel group , fix dose , multi-center dose-finding study . The patient voluntarily sign informed consent form clinical study underwent screening . After complete four-week run-in period , randomly assign either placebo group one three SK3530 group : 50mg , 100mg , 150mg . The study conduct double-blind manner . A different dose SK3530 administer subject depend assigned treatment group 8 week . Patient ’ visit take place week 4 week 8 randomization 6 7days end study .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Male , age 19 70 , suffer erectile dysfunction least past six month . Definition erectile dysfunction : “ inability attain and/or maintain penile erection sufficient satisfactory sexual performance. ” Subjects stable , heterosexual relationship single partner . In case sex partner childbearing potential age , partner consent use medically reliable contraceptive pill , injection , intrauterine device throughout whole study period . Not applicable sex partner surgically sterilize , underwent hysterectomy , one case assess acceptable investigator . Subjects eligible study subject screen test . Subjects attempt sexual intercourse four time fail least 50 % attempt fourweek runin period Subjects 5~22 score IIEF EF domain fourweek runin period Subjects voluntarily decide participate study sign inform consent form Subjects spinal injury radical prostatectomy Subjects anatomical deformity penis ( e.g . severe penile fibrosis , Peyronie ’ disease ) Subjects diagnosed primary hypoactive sexual desire Erectile dysfunction due neurogenic endocrine disorder hyperprolactinemia , low testosterone , etc . Hyperprolactinemia : blood prolactin level ≥ 3 X upper limit normal Low testosterone : blood total testosterone level &lt; low limit normal Subjects major psychiatric disorder ( include major depression schizophrenia ) , significant neurology disorder ( neurovascular disorder , etc . ) well control treatment Known history alcoholism substance abuse . Hepatic renal disease Hepatic disease : GOT , GPT ≥ 3 X upper limit normal Renal disease : blood creatinine ≥ 2.5mg/dl Currently uncontrolled diabetes mellitus ( HbA1C &gt; 12 % ) Untreated proliferative diabetic retinopathy History stroke , transient ischemic attack , myocardial infarction , unstable angina , lifethreatening arrhythmia , coronary artery bypass graft surgery within previous six month History Heart failure NYHA Class III IV , NYHA Class II within previous six month . Hypotension ( rest sit blood pressure &lt; 90/50 mmHg ) uncontrolled malignant hypertension ( rest sit blood pressure &gt; 170/100mmHg ) A blood disease might cause priapism , sickle cell disease , multiple myeloma , leukemia Known history retinitis pigmentosa History serious intestinal bleeding disorder within past year Subjects prescribe Viagra® , Cialis® , Levitra® , intracavernosal injection medication treat erectile dysfunction within one week prior screen . Subjects take one following : Nitrates/Nitric oxide ( NO ) donor ( e.g . nitroglycerin , isosorbide mononitrate , isosorbide dinitrate , amyl nitrate/nitrite , sodium nitroprusside ) Anticoagulant ( except antiplatelet agent ) Medicines affect CYP3A4 metabolism ( e.g . erythromycin , itraconazole , ketoconazole , ritonavir , saquinavir , amprenavir , indinavir , nelfinavir , cimetidine ) Androgens ( e.g . testosterone ) Antiandrogens Trazodone Known allergic hypersensitivity PDE5 inhibitor Viagra® , Cialis® , Levitra® Known responder previous treatment Viagra® , Cialis® Levitra® Subjects take clinical trial medicine ( include placebo treatment ) within previous 30 day . Subjects unable unwilling keep patient diary Subjects illiterate unable understand questionnaire patient diary Subjects clinical condition , would interfere assessment study result , opinion investigator</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>erectile dysfunction , PDE-5 inhibitor</keyword>
</DOC>